TD Cowen initiated coverage on Grace Therapeutics with a new price target
$GRCE
Biotechnology: Pharmaceutical Preparations
Health Care
TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2025 | $12.00 | Buy | TD Cowen |
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aSAH patients, today announced that results from its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH (the STRIVE-ON trial–NCT05995405) were presented at the 2025 Neurocritical Care Society annual meeting, held in Montreal, Quebec, Canada September 18-21, 2025. In an oral presentation titled Safety and Tolerability of GTx-104 (Nimodipine Injection for I.V. Infusion
Grant of First Method of Use Patent Adds New Pillar to Grace's Multi-layered Intellectual Property and Potential Market Exclusivity Protection Patent Coverage Extended to 2043 PRINCETON, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aSAH patients, today announced that the U.S. Patent and Trademark Office has issued a U.S. Patent No. 12,414,943, titled "Nimodipine Parenteral Administration". The new method of use patent, publ
PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it will be featured as a presenting company at the H.C. Wainwright 27th Annual Global Investment Conference, being held virtually and in person September 8–10, 2025. The event will take place at the Lotte New York Palace Hotel in New York City. Virtual participation will be staged simultaneously, with more than 550 company presentations sch
SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu